Schentag Jerome J, Meagher Alison K, Forrest Alan
CPL Associates, LLC, Buffalo, NY, USA.
Ann Pharmacother. 2003 Sep;37(9):1287-98. doi: 10.1345/aph.1C199.
To review in vitro and animal model studies with fluoroquinolones and the pharmacokinetic and pharmacodynamic relationships that are predictive of clinical and microbiologic outcomes and resistance. Data on fluoroquinolones are summarized and examine the premise that a single area under the inhibitory concentration-time curve (AUIC) target >125 may be used for all fluoroquinolones with concentration-dependent killing actions and against all target organisms.
Primary articles were identified by MEDLINE search (1966-February 2002) and through secondary sources.
All of the articles identified from the data sources were evaluated, and all information deemed relevant was included.
The fluoroquinolones exhibit concentration-dependent killing. This effect clearly depends on concentrations achieved, and outcomes depend on endpoints established by individual investigators. With AUIC values <60, the actions of fluoroquinolones are essentially bacteriostatic; any observed bacterial killing is the combined effect of low concentrations in relation to minimum inhibitory concentration and the action of host factors such as neutrophils and macrophages. AUIC values >100 but <250 yield bacterial killing at a slow rate, but usually by day 7 of treatment. AUICs >250 produce rapid killing, and bacterial eradication occurs within 24 hours. Disagreements regarding target endpoints are the expected consequences of comparing microbial and clinical outcomes across animal models, in vitro experiments, and humans when the endpoints are clearly not equivalent. Careful attention to time-related events, such as speed of bacterial killing, versus global endpoints, such as bacteriologic cure, allows optimal break points to be defined.
Evidence from in vitro and animal models favors the use of AUIC values >250 for rapid bactericidal action, regardless of whether the organism is gram-negative or gram-positive.
回顾氟喹诺酮类药物的体外及动物模型研究,以及预测临床和微生物学结果及耐药性的药代动力学和药效学关系。总结氟喹诺酮类药物的数据,并检验以下前提:对于所有具有浓度依赖性杀菌作用的氟喹诺酮类药物及所有目标微生物,单一的抑制浓度-时间曲线下面积(AUIC)目标>125 可适用。
通过 MEDLINE 检索(1966 年 - 2002 年 2 月)及二级来源确定原始文章。
评估从数据来源中识别出的所有文章,并纳入所有被认为相关的信息。
氟喹诺酮类药物表现出浓度依赖性杀菌作用。这种作用显然取决于所达到的浓度,而结果取决于各研究人员设定的终点。当 AUIC 值<60 时,氟喹诺酮类药物的作用基本上是抑菌性的;任何观察到的细菌杀灭是低浓度相对于最低抑菌浓度的综合作用以及宿主因素(如中性粒细胞和巨噬细胞)作用的结果。AUIC 值>100 但<250 时,细菌杀灭速度较慢,但通常在治疗第 7 天时出现。AUIC>250 时产生快速杀菌作用,细菌根除在 24 小时内发生。当终点明显不等同时,在动物模型、体外实验和人类之间比较微生物学和临床结果时,关于目标终点的分歧是预期的结果。仔细关注与时间相关的事件,如细菌杀灭速度,与整体终点,如细菌学治愈,有助于确定最佳的折点。
体外和动物模型的证据支持使用 AUIC 值>250 以实现快速杀菌作用,无论该微生物是革兰氏阴性还是革兰氏阳性。